A long-term retrospective study has found no significant survival benefit from intensifying androgen deprivation therapy (ADT) for patients with advanced prostate cancer in real-world clinical practice. The research, published in the journal JAMA Network Open, analyzed data from 160 propensity score-matched patients treated over a 25-year period.
The study compared outcomes for patients receiving standard ADT versus intensified ADT, which combines ADT with other systemic therapies like abiraterone or enzalutamide. After matching patients based on clinical characteristics, the researchers found no statistically significant difference in overall survival between the two treatment groups.
These real-world findings contrast with results from randomized clinical trials, which have shown survival benefits for ADT intensification. The authors suggest that patient selection and management in trial settings may differ substantially from routine clinical practice, potentially explaining the discrepancy.
The research highlights the importance of considering individual patient factors and the limitations of applying clinical trial results directly to broader patient populations. Further studies are needed to identify which patients are most likely to benefit from treatment intensification.
